Group 1 - The core viewpoint of the article is that Guangzhou Xinji Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Guotai Junan as its sole sponsor [1] - Xinji Pharmaceutical, founded in 2007, is an innovative pharmaceutical technology company based in Guangzhou, China, currently in the clinical stage [1] - The company has developed two core technology platforms: (i) soluble microneedle formulation technology platform and (ii) nasal inhalation formulation technology platform [1] Group 2 - Xinji Pharmaceutical has developed two core products and three additional pipeline products [1] - The first core product, dexmedetomidine microneedle patch, is designed for preoperative sedation in pediatric and adult patients, with IIa clinical trials for children already initiated in China [1] - The second core product, XJN010, is a nasal inhalation formulation developed for on-demand treatment of Parkinson's disease patients during "off" periods, currently in II phase clinical trials in China [1]
新济医药递表港交所
Zhi Tong Cai Jing·2025-12-24 07:23